MELI vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MELI

48.6
AI Score
VS
MRNA Wins

MRNA

51.3
AI Score

Investment Advisor Scores

MELI

49score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric MELI MRNA Winner
Forward P/E 36.4964 23.0415 MRNA
PEG Ratio 1.1575 0 Tie
Revenue Growth 49.0% 2.1% MELI
Earnings Growth -15.6% -85.1% MELI
Tradestie Score 48.6/100 51.3/100 MRNA
Profit Margin 6.0% -141.4% MELI
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

MELI 1M: +0.3% · 3M: -3.1% MRNA 1M: -23.7% · 3M: +20.3%

Current Technical Phase

MELI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.5 · Price: $1812.64

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $58.39

Fundamentals Snapshot

Metric MELI MRNA
Market Cap
Forward P/E 33.1 -11.0
Trailing P/E 49.5
Revenue (TTM)
Revenue Growth 0.5% 0.0%
Gross Margin 0.5% -0.7%
Operating Margin 0.1% -5.6%
EPS 37.93 -7.88
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.